The First Pouch With a Reduced-Risk OrderNarrow moat

Philip Morris International (PM) — moat facet

ZYN is the only nicotine pouch allowed to claim lower risk than cigarettes, an order no rival can copy by launching a similar can.

ZYN's most durable advantage may be a piece of paper. On 30 June 2026 the FDA granted modified risk tobacco product orders to 20 ZYN variants, which PMI described as "the first and only for a nicotine pouch product"1. Only one pouch brand in the United States may now tell adult consumers it carries lower risk than cigarettes.

ZYN regulatory path16 Jan 202520 varieties authorised2025793.7m UScans shippedH1 2026destocking,shipments -11.2%30 Jun 2026modified riskorders, 20 variantsPMI Form 10-Q Q2 2026; Q2 2026 results release; recast schedules
The only pouch with a risk claim.

The order builds on the marketing authorisation of 16 January 2025, when the FDA found that ZYN presented a "lower risk of cancer and other serious health conditions than such products" as cigarettes2. PMI has done the same with IQOS, whose exposure-modification orders were renewed to April 20313.

Regulatory orders of this kind are slow and expensive to obtain, and they cannot be copied by a rival that simply launches a similar product. The question is how much they are worth commercially. A health claim helps convert a smoker; it does less to stop an existing pouch user switching to a cheaper can.

The early evidence is mixed. American smoke-free net revenues in the first half of 2026 were $1,311 million, against $1,584 million a year earlier4, a period that included heavy distributor destocking.

The order is a narrow moat that should widen over time. American smoke-free revenue is the test; if it returns to growth in the second half of 2026 with the claim in use, the order is converting smokers, and if it does not, a unique label is not enough.

Moat trajectory: Widening

Modified risk order granted 30 June 2026.

The number that tests this moat
Reported
U.S. smoke-free net revenues, latest half
$1,311M (H1 2026), from $1,584M

Whether the unique risk claim converts into sales; another decline would say the label is not enough.

Source: PMI Form 10-Q, Q2 2026 ↗
⚠ Threats to the moat
⚠ THREAT 01
ZYN ULTRA and a Cheaper Pouch
ZYN answered competition with more pouches per can, and the American gross margin fell six points in a quarter.
References
  1. ReportedOn 30 June 2026 the FDA granted modified risk tobacco product orders to 20 ZYN variants, which PMI described as "the first and only for a nicotine pouch product".
    Philip Morris International second-quarter 2026 results release, Form 8-K exhibit 99.1 - volumes, shares, ZYN and 2026 guidance - shipment volumes, market shares, IQOS, ZYN and Japan. — Q2 2026 · publ. 22 July 2026 · source ↗
  2. ReportedThe order builds on the marketing authorisation of 16 January 2025, when the FDA found that ZYN presented a "lower risk of cancer and other serious health conditions than such products" as cigarettes.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
  3. ReportedPMI has done the same with IQOS, whose exposure-modification orders were renewed to April 2031.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
  4. ReportedAmerican smoke-free net revenues in the first half of 2026 were $1,311 million, against $1,584 million a year earlier, a period that included heavy distributor destocking.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
Sources
Generated September 26, 2026